Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nrx Pharmaceuticals Inc
(NQ:
NRXP
)
1.320
-0.060 (-4.35%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Nrx Pharmaceuticals Inc
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Investor Action Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
January 26, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against NRx Pharmaceuticals, Inc. (NRXP)
January 26, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
The Daily Biotech Pulse: Gilead's Blood Cancer Studies Placed On Partial Clinical Hold, Immunocore Gets FDA Nod, NRx Touts Positive COVID-19 Data
January 26, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
NRx Receives Initial Report of Patient Safety From 'Right To Try' Use Of Zyesami For COVID-19
January 26, 2022
NRx Pharmaceuticals (NASDAQ: NRXP) has
Via
Benzinga
Shareholder Action Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
January 25, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) Investors
January 25, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
Shareholder Action Alert: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
January 24, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) Investors
January 24, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
Shareholder Alert: Robbins LLP Reminds Investors that NRx Pharmaceuticals, Inc. (NRXP) is Being Sued for Misleading Shareholders
January 23, 2022
From
Robbins LLP
Via
Business Wire
Investor Action Reminder: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
January 21, 2022
Los Angeles - (NewMediaWire) - January 21, 2022 - The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against NRx Pharmaceuticals, Inc....
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of NRx Pharmaceuticals, Inc. (NRXP) Investors
January 21, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
Shareholder Action Notice: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
January 20, 2022
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Topics
Lawsuit
Exposures
Financial
Legal
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors
January 20, 2022
From
Glancy Prongay & Murray LLP
Via
Business Wire
Shareholder Alert: Robbins LLP Informs Investors that NRx Pharmaceuticals, Inc. (NRXP) is Being Sued for Misleading Shareholders
January 20, 2022
From
Robbins LLP
Via
Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
January 20, 2022
From
The Schall Law Firm
Via
Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors
January 20, 2022
From
The Law Offices of Frank R. Cruz
Via
Business Wire
ALERT: NRx Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NRXP; NRXPW
January 19, 2022
From
Robbins Geller Rudman & Dowd LLP
Via
Business Wire
NRX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against NRx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
January 19, 2022
From
Bragar Eagel & Squire, P.C.
Via
Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of NRx Pharmaceuticals, Inc. (NRXP) on Behalf of Investors
January 19, 2022
From
Law Offices of Howard G. Smith
Via
Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in NRx Pharmaceuticals, Inc. with Losses of $100,000 to Contact the Firm
January 19, 2022
From
The Schall Law Firm
Via
Business Wire
NRXP EQUITY ALERT: ROSEN, A LEADING LAW FIRM, Encourages NRx Pharmaceuticals, Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – NRXP; NRXPW
January 18, 2022
From
Rosen Law Firm
Via
Business Wire
NRx Pharma's Zyesami Access Expanded To COVID-19 Patients Who Exhausted All Approved Treatments
January 18, 2022
NRx Pharmaceuticals (NASDAQ: NRXP) has announced enhancements to its Expanded Access and Right to Try programs. The programs enable patients to receive Zyesami (...
Via
Benzinga
The Daily Biotech Pulse: Adagio's Antibody Effective Against Omicron, Sarepta Terminates Gene Therapy Deal, AstraZeneca Inks Oncology Pact
January 13, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio...
Via
Benzinga
NRx Pharma Files Counterclaim Against Relief Therapeutics Over COVID-19 Candidate Rights
January 13, 2022
NRx Pharmaceuticals Inc (NASDAQ: NRXP) has filed a counterclaim against its former partner, Relief Therapeutics Holdings (OTC: RLFTF), in an ongoing...
Via
Benzinga
20 Stocks Moving in Monday's Pre-Market Session
January 10, 2022
Gainers Bone Biologics Corporation (NASDAQ: BBLG) rose 32.1% to $4.53 in pre-market trading. Pluristem Therapeutics Inc. (NASDAQ: PSTI) rose 28.5% to $1.89 in pre-...
Via
Benzinga
DTST Stock Alert: The Pro Sports Deal That Has Data Storage Shares Soaring Today
January 05, 2022
Data Storage (DTST) stock is soaring higher on Wednesday after announcing a massive deal with an unnamed sports team in the U.S.
Via
InvestorPlace
WEJO Stock: 9 Things to Know About Wejo Group as Microsoft Deal Shines Light on the AV Player
January 05, 2022
Wejo Group (WEJO) stock is rising higher on Wednesday after announcing a deal with Microsoft for a vehicle data platform.
Via
InvestorPlace
NRXP Stock Alert: The Covid-19 News Lifting NRx Pharmaceuticals Today
January 05, 2022
News of a potential Covid-19 treatment breakthrough has NRXP stock rising today. Here's what you need to know about this FDA filing.
Via
InvestorPlace
RLFTF Stock Alert: What Is Going on With Relief Therapeutics Today?
January 05, 2022
RLFTF stock and NRXP stock are both gaining this morning after NRx Pharmaceuticals filed for emergency use for its Covid-19 treatment.
Via
InvestorPlace
The Daily Biotech Pulse: Pfizer-BioNTech Partner For Shingles Vaccine, Annexon Huntington Disease Study Disappoints, Amneal Buys Neurology Assets
January 05, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Annexon Announces Mixed Phase 2 Data From Huntington Disease Trial Annexon,...
Via
Benzinga
< Previous
1
2
...
6
7
8
9
10
11
12
13
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.